{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:46:40Z","timestamp":1770328000224,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00330-019-06134-7","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T15:03:01Z","timestamp":1553180581000},"page":"3935-3944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed\/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET\/CT?"],"prefix":"10.1007","volume":"29","author":[{"given":"Kazuhiro","family":"Kitajima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tazuko","family":"Tokugawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Yamakado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"key":"6134_CR1","first-page":"267","volume":"43","author":"HN Wagner Jr","year":"2002","unstructured":"Wagner HN Jr, Wiseman GA, Marcus CS et al (2002) Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 43:267\u2013272","journal-title":"J Nucl Med"},{"key":"6134_CR2","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 20:2453\u20132463","journal-title":"J Clin Oncol"},{"key":"6134_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J et al (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441\u2013449","journal-title":"N Engl J Med"},{"key":"6134_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.2013.50.3110","volume":"32","author":"TM Illidge","year":"2014","unstructured":"Illidge TM, Mayes S, Pettengell R et al (2014) Fractionated 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF\/BNLI criteria. J Clin Oncol 32:212\u2013218","journal-title":"J Clin Oncol"},{"key":"6134_CR5","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3109\/10428194.2014.949260","volume":"56","author":"AD McQuillan","year":"2015","unstructured":"McQuillan AD, Macdonald WB, Turner JH (2015) Phase II study of first-line 131I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic 18F-fluorodeoxyglucose positron emission tomography. Leuk Lymphoma 56:1271\u20131277","journal-title":"Leuk Lymphoma"},{"key":"6134_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3324\/haematol.10591","volume":"93","author":"C Bodet-Milin","year":"2008","unstructured":"Bodet-Milin C, Kraeber-Bod\u00e9r\u00e9 F, Dupas B et al (2008) Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica 93:390\u2013397","journal-title":"Haematologica"},{"key":"6134_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11307-016-1019-9","volume":"19","author":"H Jacene","year":"2017","unstructured":"Jacene H, Crandall J, Kasamon YL et al (2017) Initial experience with tositumomab and I-131-labeled tositumomab for treatment of relapsed\/refractory Hodgkin lymphoma. Mol Imaging Biol 19:429\u2013436","journal-title":"Mol Imaging Biol"},{"key":"6134_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000346436","volume":"130","author":"I Lim","year":"2013","unstructured":"Lim I, Park JY, Kang HJ et al (2013) Prognostic significance of pretreatment 18F-FDG PET\/CT in patients with relapsed\/refractory B-cell non-Hodgkin's lymphoma treated by radioimmunotherapy using 131I-rituximab. Acta Haematol 130:74\u201382","journal-title":"Acta Haematol"},{"key":"6134_CR9","first-page":"999","volume":"41","author":"T Torizuka","year":"2000","unstructured":"Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL (2000) Metabolic response of non-Hodgkin\u2019s lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med 41:999\u20131005","journal-title":"J Nucl Med"},{"key":"6134_CR10","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1007\/s00330-014-3378-4","volume":"24","author":"K Kaneko","year":"2014","unstructured":"Kaneko K, Choi I, Nakagawa M, Shinozaki K, Uike N (2014) Does tumoral 111In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing 90Y-ibritumomab radioimmunotherapy? Eur Radiol 24:3191\u20133198","journal-title":"Eur Radiol"},{"key":"6134_CR11","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068","journal-title":"J Clin Oncol"},{"key":"6134_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2967\/jnumed.108.055376","volume":"50","author":"HA Jacene","year":"2009","unstructured":"Jacene HA, Filice R, Kasecamp W, Wahl RL (2009) 18F-FDG PET\/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med 50:8\u201317","journal-title":"J Nucl Med"},{"key":"6134_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1148\/radiol.09090603","volume":"254","author":"G Storto","year":"2010","unstructured":"Storto G, De Renzo A, Pellegrino T et al (2010) Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Radiology 254:245\u2013252","journal-title":"Radiology"},{"key":"6134_CR14","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/annonc\/mdq024","volume":"21","author":"E Lopci","year":"2010","unstructured":"Lopci E, Santi I, Derenzini E et al (2010) FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. Ann Oncol 21:1877\u20131883","journal-title":"Ann Oncol"},{"key":"6134_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3413\/Nukmed-0380-11-01","volume":"50","author":"A Grgic","year":"2011","unstructured":"Grgic A, Nestle U, Scheidhauer K et al (2011) Retrospective web-based multicenter evaluation of 18F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin\u2019s lymphoma. Nuklearmedizin 50:39\u201347","journal-title":"Nuklearmedizin"},{"key":"6134_CR16","doi-asserted-by":"crossref","unstructured":"Kesavan M, Boucek J, MacDonald W, McQuillan A, Turner JH (2017) Imaging of early response to predict prognosis in the first-line management of follicular non-Hodgkin lymphoma with Iodine-131-rituximab radioimmunotherapy. Diagnostics (Basel) 7","DOI":"10.3390\/diagnostics7020026"},{"key":"6134_CR17","unstructured":"De Saint-Hubert M, Devos E, Ibrahimi A, Debyser Z, Mortelmans L, Mottaghy FM (2012) Bioluminescence imaging of therapy response does not correlate with FDG-PET response in a mouse model of Burkitt lymphoma. Am J Nucl Med Mol Imaging 2:353\u2013361"},{"issue":"9","key":"6134_CR18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1007\/s00259-010-1479-0","volume":"37","author":"L Brepoels","year":"2010","unstructured":"Brepoels L, De Saint-Hubert M, Stroobants S et al (2010) Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET. Eur J Nucl Med Mol Imaging 37(9):1688\u20131695","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6134_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2967\/jnumed.112.109397","volume":"54","author":"S Song","year":"2013","unstructured":"Song S, Xiong C, Lu W, Ku G, Huang G, Li C (2013) Apoptosis imaging probe predicts early chemotherapy response in preclinical models: a comparative study with 18F-FDG PET. J Nucl Med 54:104\u2013110","journal-title":"J Nucl Med"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-019-06134-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00330-019-06134-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-019-06134-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:12:46Z","timestamp":1584663166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00330-019-06134-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["6134"],"URL":"https:\/\/doi.org\/10.1007\/s00330-019-06134-7","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,21]]},"assertion":[{"value":"8 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Koichiro Yamakado.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Informed consent was obtained from each patient after the procedure details were fully explained.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 prospective\u2022 diagnostic or prognostic study\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}